NASDAQ:KDNY Chinook Therapeutics (KDNY) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$40.39▼$40.3950-Day Range$38.66▼$40.3952-Week Range$18.34▼$40.51VolumeN/AAverage Volume1.19 million shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Chinook Therapeutics alerts: Email Address Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Chinook Therapeutics Stock (NASDAQ:KDNY)Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Read More Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. KDNY Stock News HeadlinesMay 21, 2024 | yahoo.comChinook, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 21, 2024 | finance.yahoo.comThree Finalists Announced for the 2024 Bloom Burton AwardSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.November 1, 2023 | usnews.comChinook ElementaryAugust 8, 2023 | msn.comWedbush Downgrades Chinook Therapeutics (KDNY)August 2, 2023 | uk.finance.yahoo.comChinook Therapeutics, Inc. (KDNY)August 1, 2023 | markets.businessinsider.comExpert Ratings for Chinook TherapeuticsAugust 1, 2023 | msn.comWells Fargo Downgrades Chinook Therapeutics (KDNY)September 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.July 25, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOTJuly 16, 2023 | fool.comChinook Therapeutics (NASDAQ: KDNY)June 21, 2023 | seekingalpha.comChinook: Surprising Acquisition By Novartis, Deal Should Go ThroughJune 17, 2023 | finance.yahoo.comChinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressJune 16, 2023 | benzinga.comMoore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law FirmJune 14, 2023 | businesswire.comCHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook ...June 13, 2023 | barrons.comKDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to ShareholdersJune 13, 2023 | reuters.comNovartis buys Chinook for $3.5 bln in race to treat rare kidney diseaseJune 13, 2023 | markets.businessinsider.comWhy Are Chinook Therapeutics Shares Trading Higher TodaySee More Headlines Receive KDNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KDNY CUSIPN/A CIK1435049 Webchinooktx.com Phone(206) 485-7241FaxN/AEmployees214Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,870,000.00 Net Margins-4,199.93% Pretax Margin-4,115.56% Return on Equity-58.28% Return on Assets-44.72% Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual Sales$6.13 million Price / Sales473.15 Cash FlowN/A Price / Cash FlowN/A Book Value$6.91 per share Price / Book5.85Miscellaneous Outstanding Shares71,810,000Free Float59,749,000Market Cap$2.90 billion OptionableOptionable Beta0.34 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Eric L. Dobmeier J.D. (Age 54)Pres, CEO & Director Comp: $972.19kMr. Tom Frohlich (Age 47)Chief Operating Officer Comp: $627.44kMr. Andrew James King D.V.M. (Age 43)Ph.D., Chief Scientific Officer Comp: $651.48kMr. Eric H. Bjerkholt M.B.A. (Age 63)Chief Financial Officer Ms. Sukhi ThethySr. VP of Fin. & AccountingMs. Noopur Batsha LiffickSr. VP of Investor Relations & Corp. CommunicationsMr. Kirk D. Schumacher J.D.Sr. VP & Gen. CounselMs. Jodi JamiesonSr. VP of HRDr. Alan Glicklich M.D. (Age 60)Exec. Officer Ms. Delphine Imbert Ph.D.Sr. VP of CMC & Technical OperationsMore ExecutivesKey CompetitorsActuate TherapeuticsNASDAQ:ACTULianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXM9 Meters BiopharmaNASDAQ:NMTRPolarityTENASDAQ:PTEIQView All Competitors KDNY Stock Analysis - Frequently Asked Questions How were Chinook Therapeutics' earnings last quarter? Chinook Therapeutics, Inc. (NASDAQ:KDNY) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.03. The firm's revenue was down 32.2% compared to the same quarter last year. When did Chinook Therapeutics' stock split? Shares of Chinook Therapeutics split on Saturday, January 1st 2000. The 5-1 split was announced on Saturday, January 1st 2000. The newly issued shares were payable to shareholders after the closing bell on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. What other stocks do shareholders of Chinook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR). This page (NASDAQ:KDNY) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chinook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chinook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
